Bipolar affective disorder (manic-depressive illness) is a common, severe, chronic, and often life-threatening illness, associated with significant comorbidity. The recognition of the significant morbidity and mortality of patients with bipolar disorder, as well as the growing appreciation that a high percentage of patients respond poorly to existing treatments, has made the task of discovering new therapeutic agents, that are both efficacious and have few side effects increasingly more important. Most recent agents introduced into the pharmacopeia for the treatment of bipolar disorder have been anticonvulsants and atypical antipsychotics. We propose that novel treatments developed specifically for bipolar disorder will arise from (1) understanding more precisely the molecular mechanisms of treatments that are clearly efficacious or (2) developing medications based on the knowledge obtained of the underlying pathophysiology of bipolar disorder. Knowledge with regard to the underlying pathophysiology of bipolar disorder is increasing at a rapid pace, including alterations in intracellular signaling cascades as well as impairments of cellular plasticity and resilience in critical neuronal circuits. We propose that therapeutics designed to enhance cellular plasticity and resilience and that counter maladaptive stress-responsive systems may have considerable utility for the treatment of bipolar disorder. Therapeutic strategies designed to address cellular resilience and plasticity include the regulation of neurotrophic pathways, glucocorticoid signaling, phosphodiesterase activity, and glutamatergic throughput and mitochondrial function. While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness.
Bipolar disorder (manic-depressive illness) is a common, severe, chronic, and often life-threatening illness, associated with significant comorbidity. 1 It has historically been assumed that-in contrast to dementia praecox (schizophrenia)-bipolar disorder is an episodic illness with full recovery between episodes. However, studies that are more recent have clearly shown that this may only represent the situation for a minority of subjects. A number of studies and analyses have indicated that for a large percentage of patients, the outcome is quite poor, with high rates of relapse, chronicity, lingering residual symptoms, subsyndromes, cognitive and functional impairment, and psychosocial disability. Furthermore, suicide is estimated to be the cause of death in up to 15% of individuals with mood disorders, and, in addition to suicide, many other deleterious health-related effects are increasingly being recognized. Indeed, there is a growing appreciation that, far from being diseases with purely psychological manifestations, mood disorders are systemic diseases with deleterious effects on multiple organ systems. The recognition of the significant morbidity and mortality of patients with bipolar disorder, as well as the growing appreciation that a significant percentage of patients respond poorly to existing treatments, has made the task of discovering new therapeutic agents, that are both efficacious and have few side effects, increasingly more important. In recent years, there has been an explosion in the number of options available for the treatment of bipolar disorder with a parallel and unprecedented increase in the interest in the treatment of bipolar disorder by pharmaceutical companies, clinicians, researchers, and indeed the public. There are a number of newer pharmacological agents that are rapidly being introduced into the market and used by clinicians for the management of bipolar patients. However, largely, these simply represent agents developed for other disorders (notably epilepsy or schizophrenia), following which their utility is investigated for the treatment of bipolar disorder. Thus, the two categories of drugs that have received much attention by clinicians and researchers alike as putative treatments for bipolar disorder are anticonvulsant and antipsychotic medications. Significant advances were achieved with the development of the atypical antipsychotic drugs compared to the typical antipsychotic drugs. They are associated with lower rates of extrapyramidal symptoms and tardive dyskinesia, and are more efficacious both in the treatment of negative symptoms of schizophrenia and in improving the quality of life. The atypical antipsychotic drugs were also noted to have significant thymoleptic properties early on in their development.
As a consequence, almost as rapidly as anticonvulsants are being introduced into the market for the management of epilepsy and atypical antipsychotic drugs for the treatment of schizophrenia, these drugs are being used by clinicians for the treatment of bipolar disorder. This practice undoubtedly has resulted in large part from the appalling dearth of pharmacologic agents specifically developed for the treatment of bipolar disorder. In this perspectives paper, we outline approaches that are currently underway for the development of novel therapeutics specifically for the treatment of bipolar disorder.
Approaches for developing novel therapeutics for a complex disorder such as bipolar illness might occur in one of two ways:
(1) Understanding the precise biochemical targets (both direct and long-term) of antimanic/mood stabilizers currently in use and using the knowledge gained to design drugs that are more specific to those biochemical target(s). (2) Understand the pathophysiology of the illness and utilize that knowledge to design therapeutics that control core bipolar symptomatology and either attenuate or prevent the deleterious systemic effects of the illness.
Here, we focus on the second approach; in an accompanying article within this issue, we discuss medication development approaches utilizing the first approach. 2 Knowledge regarding the underlying pathophysiology of bipolar disorder is increasing at a rapid pace, with most theories suggesting that an underlying genetic diathesis interacts with environmental factors. Extensive genetic studies are underway 3 and it is likely that their fruition combined with the knowledge obtained in other fields such as epidemiology, neuroimaging, and neuropathology will allow for a more precise understanding of the disease process(s) involved.
A number of neurobiological mechanisms have been proposed to explain the etiology of bipolar disorder, with monoamines traditionally receiving the greatest interest. Herein, we focus on more recent hypotheses, describing how impairments of neuroplasticity and cellular resilience may contribute to the underlying pathophysiology. While traditionally viewed exclusively as a neurochemical disorder, recent evidence suggests the possibility that the underlying primary pathophysiology of bipolar disorder may involve alterations in intracellular signaling cascades that produce not only functional but also neuromorphological impairments, rather than specific alterations in isolated neurochemicals per se. In this regard, it is worth noting that increasing number of neuroimaging, neuropathological, and biochemical studies consistently suggest that impairments in neuroplasticity and cellular resilience are present in patients who suffer from severe, recurrent mood disorders. In the following sections, we describe studies identifying possible structural, functional, and cellular abnormalities associated with bipolar disorder and discuss the potential cellular underpinnings of these micro-and macro morphological brain changes. We suggest that therapeutics designed to enhance cellular plasticity and resilience and that counter maladaptive stress-responsive systems may have considerable utility for the treatment of severe mood disorders.
Evidence for impairments of structural plasticity and cellular resilience in mood disorders
Methodologies to investigate structural and functional deficits within the human brain have exponentially increased in recent years allowing for a more complete and intensive analysis of potential deficiencies in the brains of patients suffering from neuropsychiatric disorders. Thus, it is now possible to discern relatively subtle differences in cerebral blood flow, receptor density, or in macroscopic brain structure. Likewise, post-mortem studies of the brain are enhanced with technological advances that allow for relatively unbiased observations of cell density, morphology, and size. The functional and morphometric findings in bipolar disorder have been extensively reviewed elsewhere; 4-13 here we provide a brief overview of these findings.
In toto, positron emission tomography (PET) imaging studies have revealed multiple alterations of regional cerebral blood flow (CBF) and glucose metabolism in limbic and prefrontal cortical (PFC) structures in patients with mood disorders. Overall, most of these studies implicate the limbic-thalamiccortical and limbic-cortical-striatal-pallidal-thalamic circuits, involving the amygdala, orbital and medial PFC, and anatomically related parts of the striatum and thalamus in the pathophysiology of mood disorders (see Sheline, 4 Drevets, 5 Manji et al, 6 Drevets 7 for a review). Recent morphometric magnetic resonance imaging (MRI) and post-mortem investigations have also demonstrated abnormalities of brain structure that correspond to the abnormalities of metabolic activity (discussed in Manji et al, 6 Drevets, 7 Manji and Duman 8 )
. Structural imaging studies demonstrate reduced gray matter volumes in areas of the orbital and medial PFC, temporal lobe, and enlargement of third ventricle in subjects with mood disorders compared to healthy controls (reviewed in Drevets, 9 , Strakowski et al, 10 Beyer and Krishnan 11 ). Also consistent is the increased presence of white matter hyperintensities (WMH) in the brains of elderly depressed patients, and both young and elderly patients with bipolar disorder (reviewed in Lenox et al 14 ) . While there is a growing awareness of the genetic influences on WMH, and their possible impact on neuropsychological functioning, 15 there are multiple other causes including cerebrovascular accidents, demyelination, loss of axons, dilated perivascular space, minute brain cysts, and necrosis (see Lenox et al 14 for a review). Diffusion tensor imaging (DTI) of brain tissue has been utilized to study possible white matter tract disruption in mood disorders. 16 This procedure measures the apparent diffusion coefficient (ADC), or isotropic diffusion, and anisotropy, or diffusion as influenced by tissue structure. Taylor and co-workers found that WMH showed higher ADC and lower anisotropy than normal regions, with gray matter showing similar trends. Recent evidence suggests that subcortical hyperintensities are correlative with cortical gray matter changes. 17, 18 Together, these results support the contention that WMH damage the structure of brain tissue and likely disrupt the neuronal connectivity necessary for normal affective functioning. Although the cause of WMH in mood disorders is unknown, their presence-particularly in the brains of young bipolar patients-suggests importance in the pathophysiology of the disorder. 14, 19 Relatively recent post-mortem neuropathological studies are complementary, showing reductions in cortex volume, and region-and layer-specific reductions in number, density, and/or size of neurons and glial cells in the subgenual PFC, orbital cortex, dorsal anterolateral PFC, amygdala, and in basal ganglia and dorsal raphe nuclei in individuals with bipolar disorder and other severe mood disorders compared to controls (reviewed in Manji and Duman, 8 Cotter et al 12 Rajkowska 13 ). It is important to note, however, that it is not currently known if these alterationswhether they be functional and structural imaging or post-mortem-constitute developmental abnormalities conferring vulnerability to severe mood episodes, compensatory changes to other pathogenic processes, the sequelae of recurrent affective episodes, comorbidity, pharmacological treatments, or solely epiphenomenon that lack real significance in the acute signs and symptoms of these disorders (although they very likely do contribute to the longterm functional deterioration observed in many patients). Understanding these issues will partly depend on experiments that delineate the onset of such abnormalities within the illness course and determine whether they antedate mood episodes in high-risk individuals. Furthermore, there is no total reproducibility among either the neuroimaging or post-mortem studies. This may be representative of variations of experimental design (including medication effects), an effect of low sample size, or difficulty in clearly defining disease phenotypes within a heterogeneous group of disorders. Thus, further study is required in order to understand if more rigorously defined subtypes of bipolar disorder and other mood disorders are associated with any particular or specific biological alteration. 14 Stress and glucocorticoids modulate neural plasticity: implications for mood disorders and the development of improved therapeutics
In developing hypotheses with regard to the pathogenesis of these histopathological changes in mood disorders, the alterations in cellular morphology resulting from various stressors have been the focus of considerable recent research (reviewed in D'sa and Duman 20 ). Thus, although mood disorders have a strong genetic basis, considerable evidence has shown that severe stressors are associated with a substantial increase in risk for the onset of mood disorders in susceptible individuals. The hypothalamus-pituitary-adrenal (HPA) axis is a major pathway by which stress exerts its effects on the brain and other organ systems. This pathway represents the primary 'stress' pathway in humans and other mammals, whereas the lateral ventricular nucleus of the hypothalamus releases corticotropin-releasing hormone/factor (CRH/F), which stimulates the production of adrenocorticotropin-releasing hormone (ACTH) by the pituitary. This latter hormone stimulates the production of glucocorticoids by the adrenal gland. Cortisol is considered a primary stress hormone of the body, having varied effects on metabolism, neurovegetative behaviors of organisms, and a multitude of effects on the functions of neurons and neuronal systems (Figure 1 ).
Most studies of atrophy and survival of neurons in response to stress, as well as hormones of the HPA, have focused on the hippocampus. This is due, in part, to the well-defined and easily studied neuronal populations of this limbic brain region, including the dentate gyrus granule cell layer and the CA1 and CA3 pyramidal cell layers. Another major reason is that the highest levels of glucocorticoid receptors are expressed in this brain region. 21 However, it is clear that stress and glucocorticoids also influence the survival and atrophy of neurons in other brain regions (eg PFC; see below) that have not yet been studied in the same detail as the hippocampus.
One of the most consistent effects of stress on cellular morphology in preclinical models is atrophy of hippocampal neurons (for reviews, see Sapolsky, 22 McEwen. 23 ) This atrophy is observed in the CA3 pyramidal neurons, but not in other hippocampal cell groups (ie CA1 pyramidal and dentate gyrus granule neurons). The stress-induced atrophy of CA3 neurons (ie, decreased number and length of the apical dendritic branches) occurs after 2-3 weeks of exposure to restraint stress or more long-term social stress, and has been observed in different species including rodents and tree shrews. 22, 23 Atrophy of CA3 pyramidal neurons also occurs upon exposure to high levels of glucocorticoids, suggesting that activation of the HPA axis likely plays a major role in mediating the stress-induced atrophy. [23] [24] [25] Neurogenesis in the adult brain is also the target of major research on the role of stress and the HPA axis. The localization of pluripotent progenitor cells and neurogenesis occurs in restricted brain regions, with the greatest density of new cell birth observed in the subventricular zone and the subgranular layer of the hippocampus. Neurogenesis in the hippocampus is increased by enriched environments, exercise, and hippocampal-dependent learning. [26] [27] [28] Up-regulation of neurogenesis in response to these behavioral stimuli and the localization of this process to the hippocampus has led to the proposal that new cell birth is involved in learning and memory. 26 Studies have shown that decreased neurogenesis occurs in response to both acute and chronic stress (see Gould et al. 26 ). Furthermore, it has been shown that removal of adrenal steroids (i.e. adrenalectomy) increases neurogenesis, and that treatment with high levels of glucocorticoids reproduces the downregulation of neurogenesis that occurs in response to stress.
Lowering glucocorticoid levels in aged animals restores neurogenesis to levels observed in younger animals, indicating that the population of progenitor cells remains stable but that it is inhibited by glucocorticoids. 29 Antidepressants 30 and lithium 31 increase neurogenesis in the hippocampus. However, while the importance of neurogenesis in mood disorder treatment and pathophysiology is still a matter of important debate, Santarelli et al. 32 recently conducted a series of very critical experiments. Mice were given oral fluoxetine, imipramine, desipramine, haloperidol, or vehicle for 28 days, applying the novelty-suppressed feeding test as a model for antidepressant efficacy. This group noted a 35% improvement in speed for retrieving food or water in mice taking antidepressants (fluoxetine, imipramine, or desipramine). In a second experiment, they found a 60% increase in BrdU-positive cells in the dentate gyrus after 11-28 days of treatment with fluoxetine. To test whether hippocampal neurogenesis is necessary for the antidepressants effect, they exposed mice to X-rays directed at the hippocampus, leading to an 85% reduction in BrdU-positive cells in the subgranular zone. These mice were then treated with fluoxetine, imipramine, or vehicle for 28 days. The previously noted effect of antidepressants on the novelty-suppressed feeding test was not seen in irradiated mice, suggesting that behavioral effects of chronic use of antidepressants may be mediated by new neurons in the hippocampus. 32 However, several lines of evidence suggest that it may be premature to conclude that hippocampal neurogenesis is causally linked to the etiology and treatment of depression. Thus, Vollmayr et al. 33 have undertaken a series of studies to determine if the inescapable foot shock learned helpnessness model is associated with reduced hippocampal proliferation in a temporal time frame consistent with the behavioral deficits. They did not find a significant reduction in cell proliferation at a time when the helpless behavior was first observed. In follow-up studies, they utilized restraint stress to decrease the rate of cell proliferation 40%; subsequent investigation showed that these animals did not develop learned helplessness at a higher rate than the control animals. Most recently, large-scale clinical studies have shown lack of antidepressant efficacy of an NK1 antagonist; these results argue against a simple 'neurogenesis hypothesis' somewhat since both NK1 antagonists, and NK1 knockout mice show increased neurogenesis. 34, 35 It may therefore be more appropriate to consider the changes in the context of broader impairments of cellular plasticity and resilience, rather than a limited neurogenesis hypothesis model. These series of preclinical findings in the hippocampus are consistent with the clinical findings showing that subjects with depression of longer illness duration and multiple hospitalizations (associated with prolonged hypercortisolemia 22 ) have smaller hippocampal volumes. 36, 37 Antidepressant treatment may offer some protection against Figure 1 Harmful effects of stress, HPA axis activation, and glutamate on neurons. Depicted here are multiple mechanisms by which stress, and potentially affective episodes, may attenuate cellular resiliency, thereby resulting in atrophy, death, and endangerment of hippocampal neurons. Three primary mechanisms appear to be: (1) excessive NMDA and non-NMDA glutamatergic throughput; (2) downregulation of cell surface glucose transporters, which are involved in bringing glucose into the cell. Reduced levels of glucose transporters thus reduce the neuron's energetic reservoir, making them susceptible to energy failure when faced with excessive demands; (3) reduction in the levels of neurotrophic factors such as BDNF, which is essential for the neuron's normal trophic support and synaptic plasticity; (4) a reduction in glial cells may contribute to impairments of neuronal structural plasticity by reducing the neuron's energy supply and reduced glialmediated clearing of excessive synaptic glutamate. NMDA, N-methyl-aspartate glutamate receptor; CRF, corticotropinreleasing factor; GR, glucocorticoid receptor; BDNF, brainderived neurotrophic factor. Modified, and reproduced, with permission from. 228 hippocampal volume loss. 38, 39 It is important to note, however, that some studies suggest that small hippocampi are-at least in part-an inherited characteristic of the brain and predisposes to (rather than represents the sequelae of) psychiatric disorders. 40, 41 These observations highlight the need for caution in attribution of causality in the cross-sectional human morphometric studies of the hippocampus discussed above and the preclinical data on the effects of stress.
Although not as extensively studied as the hippocampus, preclinical research has also demonstrated histopathological changes in rat PFC after corticosterone administration. 42 Wellman investigated pyramidal neurons in layers II-III of medial PFC, and quantified dendritic morphology in three dimensions. This study demonstrated a significant redistribution of apical dendrites in corticosterone-treated animals, with the amount of dendritic material proximal to the soma increased and distal dendritic material decreased. These findings suggest that stress may produce a significant reorganization of the apical dendritic arbor from medial PFC in rats. More recently, Lyons et al 43 demonstrated that 4 years after a brief stressor (intermittent postnatal separations from maternal availability) young adult squirrel monkeys showed significantly larger right ventral medial prefrontal volumes. 43 Neither overall brain volumes nor left prefrontal measures were altered, suggesting selective (rather than nonspecific) effects. It is interesting to speculate that these preclinical findings are related to the clinical observations of reduced size of PFC regions, gray matter changes, and post-mortem alterations of neurons and glial cells in patients with mood disorders.
Evidence for impairment of HPA axis in mood disorders
Evidence of HPA axis activation in bipolar disorder is suggested by multiple lines of evidence. Cushing's syndrome secondary to chronic high levels of endogenous glucocorticoids is associated with a number of psychiatric and psychological disturbances, regardless of its etiology. Major depression, mania, anxiety disorders and cognitive dysfunction/delirium, and hippocampal atrophy have commonly been reported. 44, 45 For example, in a prospective study 81% of subjects diagnosed with Cushing's developed a psychiatric disorder, most frequently a mood disorder. 46 Interestingly, treatment with antiglucocorticoid therapeutics has been reported to result in an improvement in mood/cognitive dysfunction, 46 as well as an increase of hippocampal volume in proportion to the treatment-associated decrement in urinary-free cortisol after corrective surgery. 47, 48 In noncushingoid subjects, multiple case reports, as well pharmacoepidemiological studies, have reported the effects of exogenous steroids on mood (reviewed in Brown et al 49 ). In a recent review, Sirois 50 found that 75% of patients treated with exogenous corticosteroids exhibited affective symptoms, including mania and depression. At least one report found that mania or hypomania was reported to occur on the day of treatment with corticosteroids and depression was seen on alternate days of treatment. 51 Measurements of HPA activity in patients are also overwhelmingly supportive. Indeed, overactivity of the HPA axis in depression (either unipolar or bipolar) is among the most consistently replicated biological findings in psychiatry. These include lack of dexamethasone suppression of endogenous cortisol levels, increased ACTH response to CRF, and altered responses to the combined dexamethasone/corticotropin release hormone (DEX/CRF) challenge test. While we do not describe this well-defined phenomenon extensively here, we refer the interested reader to an excellent review in Plotsky et al. 52 Detailed studies of glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) in subjects with mood disorders are still ongoing. However, postmortem studies in patients have shown significantly lower glucorticoid receptor (GR), mineralocorticoid receptor (MR) protein, and mRNA levels in the PFC compared to controls. 53 GR mRNA levels were reported to be decreased in layers III and VI in the entorhinal cortex in patients with mood disorders. 54 Nemeroff et al 55 have additionally shown a marked decrease in CRF binding sites in the frontal cortex of suicide victims. In an in vivo study of MR function in subjects with depression using spirinolactone (an MR antagonist), Young et al 56 found that subjects with depression had higher functional activity of the MR system, with an increased secretion of cortisol in response to spirinolactone in comparison to matched controls. 56 Animal models using knockout genes or antisense probes have been extremely valuable in understanding the HPA axis, and support its relevance in the pathophysiology and treatment of mood and anxiety disorders. See Gould et al 57 for a complete description of these studies.
Is targeting the HPA axis a relevant strategy for the treatment for severe mood disorders?
Owing to the evidence reviewed above, there is a growing appreciation that abnormalities of the HPA axis may play a role in mediating the phenotypic expression of certain affective states, 58 and, not surprisingly, there is increasing interest in targeting this system for the development of novel therapeutics. Published double-blind, placebo-controlled clinical studies to modulate the HPA axis have employed inhibitors of glucocorticoid synthesis, 59, 60 antagonists of the GR, 61, 62 hydrocortisone to downregulate the HPA axis (as a proof of concept study in DeBattista et al 63 ) and dehydroepiandrosterone. 64, 65 See Table 1 for a summary of these and additional open-label studies, including a CRF 1R antagonist trial. Some of these drugs have been investigated for proof of concept, and it is expected that modified and 66 Holmes et al 67 for a review). Preclinical studies have shown that CRF 1 antagonists reduce CRF-induced ACTH release and CRF-induced cAMP production.
Antalarmin, a novel pyrrolopyrimidine compound, 68 in oral doses of 20 mg/kg in primates significantly diminished the CRF-stimulated ACTH release, and the pituitary-adrenal, sympathetic, and adrenal medullary responses to stress and also reversed stress-induced inhibition of exploratory and sexual behaviors. 69 Using the chronic stress model in mice, both antalarmin (10 mg/kg) and fluoxetine (10 mg/kg) were found to improve measures of physical state, weight gain, and emotional response in the light-dark test compared to stressed, untreated animals. 70 CP-154,526, developed by Pfizer, has been evaluated in animal paradigms for anxiety. It has a high penetrability similar to antalarmin. 71 Mansbach et al 72 have shown its efficacy in the learned helplessness model of depression in rats. SSR125543A, a 2-aminothiazole derivative, which displays high affinities for human CRF R1 receptors, has shown efficacy in the forced swim test model and in chronic mild stress model in rats in a study comparing it to antalarmin and fluoxetine. 73 In other studies, CRA 1000, a nonpeptide pyrimidine CRF 1 antagonist being developed by Taisho Pharmaceuticals, 74 reduced immobility in the learned helplessness paradigm in male Wistar rats when given by intraperitoneal injection. 75 DMP696, developed by Dupont, is a selective, potent, and highly bioavailable nonpeptide CRF 1R antagonist. It has been tested in behavioral models of anxiety and is being tested in behavioral paradigms for depression. 76 Interestingly, R-121919 reduced anxiety and depressive symptoms in patients with major depression in an open-label clinical trial. 77 The clinical development of the compound was discontinued probably because of two healthy volunteers developed elevated liver enzymes after receiving a high dose of R-121919. 78 Recently, however, in an extended data report of the clinical study in major depression patients, no serious side effects were noted in the hypothalamic-pituitary-gonadal system, the hypothalamic-pituitary-thyroid axis, the renin-angiotensin system, and prolactin or vasopressin secretion. In addition, no effects on clinical laboratory parameters (including liver enzymes) were observed, encouraging the development of CRF 1R antagonists as antidepressant medications. 78 Wolkowitz Dehydroepiandrosterone Dehydroepiandrosterone (DHEA) serves as a precursor for both androgenic and estrogenic steroids and together with its sulfated form (DHEA-S) are secreted by the adrenal gland and also produced in the CNS. Thus, DHEA and DHEA-S are neuroactive steroids that have a number of effects that can be described as 'functional antagonism' of the actions of glucocorticoids (DHEA does not directly interact with the glucocorticoid receptor, and there is no known receptor for DHEA in any tissue). 79 Among its effects, DHEA counteracts the actions of glucocorticoids to inhibit memory and primed-burst potentiation (a form of long-term potentiation), and antagonizes oxidative damage in the brain (and in other organs) produced by acute hyperglycemia. Although mediated by an unknown cellular and molecular mechanism, DHEA also interacts with neurotransmitters (serotonin, gamma amino butyric acid, excitatory amino acids, and dopamine), in addition to its glucocorticoid antagonism (reviewed in McEwen   79 ). Its antidepressant efficacy has been suggested by clinical trials in dysthymic and depressed patients. Wolkowitz and coworkers reported a case series comprising of six middle-aged and elderly major depression patients with low basal plasma DHEA and/or DHEA-S levels who received DHEA 30-90 mg/day for 4 weeks. A decrease in depression ratings and an improvement in memory performance correlated to increases in plasma levels of DHEA and DHEA-S, were observed. 80 The effects of DHEA were also investigated in a double-blind, placebo-controlled, randomized crossover treatment study with 90 and 450 mg of DHEA, in patients with midlife-onset dysthymia (a total of 6 weeks on medication and 6 weeks on placebo). Of 17 patients, 15 completed the study and 60% of the patients responded to DHEA compared with 20% on placebo. 65 Finally, a double-blind, placebo-controlled study was conducted in 22 patients with major depression (medication-free or on stabilized antidepressant regimens). Utilizing DHEA at a maximum dose of 90 mg/day or placebo for 6 weeks, 45% of the patients showed a decrease of 50% or greater in depressive symptoms, while none in the placebo group. 64 
GR antagonist
Mifepristone (RU-486) is a nonselective antagonist of the GR receptor that has shown efficacy in psychotic depression 61, 81, 82 and on which there are ongoing trials in bipolar disorder (reviewed in Manji et al 83 ) . Preliminary data with mifepristone (600 mg) compared to placebo in 19 subjects with bipolar depression were recently presented. 84 This group found a beneficial effect on mood and neurocognitive functioning. In a separate study not yet published, 208 patients were randomized to receive 7 days of mifepristone or placebo in addition to their ongoing treatment for psychotic mayor depression. Although both groups improved significantly, with no statistical difference among them, a post hoc analysis revealed that mifepristone patients improved more rapidly than the placebo group. 85 Other GR antagonists being developed are ORG 34517 (Organon), AL082D06 (Abbott), and Cyproterone Acetate (Schering). Bachman et al 86 
Cyproterone Acetate is available outside the US as an antiandrogen approved for paraphilias. It is used as a contraceptive agent added to estradiol, combination that is also widely used for hair growth. Honer et al 89 have recently reported its GR antagonism properties and while it could be tested in depression, it is unlikely to be clinically useful because of its antiandrogenic properties and risk of severe liver damage.
Inhibition of glucocorticoid synthesis has also been investigated as an antidepressant strategy (considering the risk for hypoadrenalism) in unipolar and bipolar patients and it has included the compounds ketoconazole (that possesses risk for hepatotoxicity and drug interaction), metyrapone, and aminogluthethimide. See a review of relevant findings in Table 1 .
Modulation of glutamate receptors may regulate neuroplasticity and cellular resilience: therapeutic implications
One major neurotransmitter system regulated by glucocorticoids is the glutamatergic system. Regulated either via glucocorticoids or through alternative mechanisms, abnormal activity of the glutamatergic system represents a likely contributor to impairments in brain neuroplasticity and cellular resilience observed in patients with bipolar disorder. Glutamate is the major excitatory synaptic neurotransmitter in the brain and has several important roles including mediating neurotransmission across excitatory synapses and regulating numerous physiological functions in the mammalian central nervous system (CNS), such as synaptic plasticity, learning, and memory. [90] [91] [92] [93] Several treatment strategies have been implemented to reduce glutamate-mediated excitotoxicity, which results in robust neuroprotective effects in a variety of preclinical paradigms; however, the data in humans with neurodegenerative disease are more equivocal. The same antiglutamatergic neuroprotective strategies used for these neurodegenerative disorders may have an important role in patients with mood disorders and are currently being tested in 'proof-of-concept' studies in patients with mood disorders (see below). Glutamate levels may rise to excitotoxic levels within minutes of sudden insults such as cerebral trauma or ischemia, adding stress to the normal compensatory processes by overloading the capacity of the glutamate transporters. 94 Glutamate then binds the receptor complex and under certain conditions may further add to this insult by triggering a series of downstream toxicity pathways (Figure 1) .
Noting the findings of the dysregulation of the HPA axis in mood disorders, it is worth noting that glucocorticoids have been demonstrated to exacerbate neuronal damage in models of excitotoxicity due to increased glutamatergic transmission. 95 Microdialysis studies have shown that stress increases extracellular levels of glutamate in hippocampus, and N-methyl-Daspartate (NMDA) glutamate receptor antagonists attenuate stress-induced atrophy of CA3 pyramidal neurons (for a review, see McEwen, 23 Sapolsky 95 ). Furthermore, subsets of hippocampal neurons that show damage after kainate-induced seizures show the highest expression of GRs, with very high colocalization of GR immunoreactivity with AMPA receptors (AMPARs), 96 suggesting that the survival of neurons with high glutamatergic input may be particularly regulated by GC. GCs can also directly prolong NMDA responses, causing significantly more calcium entry, 97 with higher calcium levels being a possible means of endangering neurons to subsequent injury. In addition, GC can alter expression patterns of glutamate receptors to induce possibly dramatic changes in glutamatergic signaling in the CNS. 98, 99 Endogenous activation of group II/III metabotropic glutamate receptors has recently been shown to inhibit the HPA axis, 100 and human studies has suggested that at least some NMDA antagonists can increase cortisol levels. 101 Therefore, the overlap between the HPA axis and glutamatergic systems may indicate that pathologic changes in one parameter might induce maladaptive states of the other and that treatments improving one parameter might also provide beneficial effects to the other.
Owing to the role of glutamate in neuronal plasticity, and independent of interactions with the HPA axis, modulation of the glutamatergic system is being investigated as an antidepressant strategy in a number of ongoing clinical studies by our group and others (see Zarate et al 102 for review). Glutamate exerts its action at the presynaptic and postsynaptic level through the stimulation of specific receptors that can be classified by structural characteristics (Figure 2 ): the first group, 'ionotropic glutamate receptors', are ion channels that when stimulated open the channel pore allowing sodium, potassium, or calcium to flow freely into the cell. This opening of the pore changes the polarization of the neuronal surface and often activates intracellular signaling pathways. The second group, 'metabotropic receptors', are G-proteincoupled receptors that exert their actions through second messenger pathways. Therapeutics can target these receptors; it is additionally possible to also target the release of glutamate before it binds to either the ionotropic or metabotropic receptors. Therapeutics directed at these different targets may result in the modulation of the glutamatergic system and ultimately to mood-enhancing effects (see Figure 2 for further information with regard to classification of glutamate receptors). In the following sections, we further discuss inhibition of glutamate release, inhibition of ionotropic glutamate receptors, and modulation of metabotropic glutamate receptors as general mechanisms to adjust the function of the glutamatergic system. We follow with a discussion of some glutamatergic modulators that may possibly have a role in the treatment of mood disorders. These agents include riluzole, memantine, felbamate, and zinc, glutamatergic modulators that appear to have neuroprotective properties in preclinical models with an apparently low risk of inducing psychotomimetic symptoms compared to certain types of NMDA antagonists (such as PCP and ketamine). Testing different glutamate-modulating agents that affect different components of glutamatergic neurotransmission may help discern what aspects of this system are most relevant.
Inhibition of glutamate release
Clinical evidence that modulation of glutamate levels may be important in the treatment of mood disorders comes from the clinical use of the anticonvulsant lamotrigine. 103, 104 Lamotrigine is FDA approved as adjunctive therapy for adults with partial seizures and as adjunctive therapy in the generalized seizure of Lennox-Gastaut syndrome in pediatric and adult patients. Lamotrigine has recently received FDA approval for long-term maintenance treatment of bipolar disorder, and appears to be most useful for the treatment of bipolar depression and in preventing mood episode relapse. 103, 105 While lamotrigine has multiple cellular effects, an inhibition of an excessive release of glutamate appears to be important to its mechanism of action. [106] [107] [108] Lamotrigine reduces the hyperglutamatergic consequences of NMDA receptor dysfunction (cognitive dysfunction learning and memory impairment and psychomimetic effects) caused by ketamine in healthy volunteers. 109 There is now evidence that another drug that inhibits the release of glutamate (riluzole) also has antidepressants properties (see Zarate et al 126 and the discussion below).
Riluzole
Riluzole is a neuroprotective agent with anticonvulsant properties. Chemically, riluzole is 2-amino-6-(trifluoromethoxy) benzothiazole, and can easily cross the blood-brain barrier. 110 Riluzole is the only drug currently approved (by the FDA in US, CPMP in Figure 2 The glutamatergic system as a target of novel medications. Glutamate is synthesized in neuron from a-ketoglutarate through the tricarboxylic acid (TCA) cycle. After released, glutamate is reuptaken by glutamate transporters, shown in glia (GTg) and a presynaptic neuron (GTn). In the glia, glutamate is catabolized to glutamine (through the enzyme glutamine synthetase), diffuses to the neurons, and is then metabolized back to glutamate (through the enzyme glutaminase). The different glutamate receptors and the presumed antiglutamatergic drug site of action are presented in the figure. Glutamate (Glu) exerts its action at the presynaptic and postsynaptic level through the stimulation of specific receptors that can be classified by structural characteristics: the first group, 'ionotropic glutamate receptors' are ion channels that when stimulated open the channel pore allowing sodium, potassium, and calcium to flow freely into the cell. This opening of the pore changes the polarization of the neuronal surface and activates intracellular signaling. NMDA and AMPA are ionotrophic glutamate receptors. Activation of these receptors allows the entry into the cell of primarily calcium and sodium, respectively. The second group metabotropic glutamate receptors', mGluR are G-protein-coupled receptors, which directly act through second messenger pathways. Riluzole is a glutamate release inhibitor (acting through blockade of Na þ voltage dependent channels), a GABA A agonist, and probably an AMPA and Kainate antagonist. Lamotrigine has a number of biological effects (eg inhibition of Na þ voltage-depend channels), including the inhibition of glutamate release. Memantine is a noncompetitive antagonist NMDA receptor. Felbamate is a noncompetitive NMDA receptor antagonist (at glycine NR1 and glutamate NR2B subunits), an AMPA receptor antagonist, a mGlu group I receptor antagonist, and a glutamate release inhibitor (acting through blockade of Ca 2 þ and Na þ voltage-dependant channels). Ketamine is a high-affinity NMDA receptor antagonist. Dcycloserine is a partial agonist at the NMDA receptor glycine (Gly) site. At high does amantadine reduces NMDA receptor function by approximately 50%, an effect attributed to its instability within the NMDA receptor channel. 229, 230 Zinc is a potent inhibitor of the NMDA receptor complex. See text and 102, 195 for thorough description. AMPAkines allosterically produce positive modulation of AMPA receptors and have actively been studied in the treatment of schizophrenia. 177 Studies have shown that the biarylpropylsulfonamide AMPA receptor potentiators (LY392098 and LY451616) have antidepressant effects in animal models of depression. 126 Europe, and MHW in Japan) for the treatment of ALS. Evidence from a variety of studies with experimental animals and with humans indicate that riluzole is devoid of the psychotomimetic or other behavioral side effects commonly associated with excitatory amino-acid antagonists. 111, 112 In contrast to memantine (discussed below), riluzole does not act directly on the NMDA receptor. 113 The mechanism of action by which riluzole exerts its glutamatergic effect has been reported to be through the inhibition of voltagedependent sodium channels in mammalian CNS neurons 114, 115 and the reduction of glutamate release. 116 However, tetrodotoxin, a sodium channel blocking agent, failed to block the inhibitory effect of riluzole on glutamate, suggesting that the effects of the drug are not exclusively mediated by its action on sodium channels. 117 The anticonvulsant activity of riluzole may also be due to its effect on neurotransmission mediated by the AMPA/KA receptors, 113, [118] [119] [120] [121] however, the mechanism by which riluzole interacts with these receptors remains unclear. Recent studies have shown that riluzole stimulates the synthesis of growth factors including BDNF in cultured mouse astrocytes. 122 This finding is of interest in that previous studies demonstrated that antidepressant and mood stabilizer treatments increase the expression of BDNF in rat hippocampus and that infusion of BDNF into the dentate gyrus of hippocampus produces antidepressant effects in behavioral models of depression. 123 Recent case reports, [124] [125] and an open label clinical trial, 126 support the efficacy of riluzole in treatmentresistant depression. In the latter, 19 treatmentresistant patients with unipolar depression received riluzole monotherapy for up to 6 weeks. Patients taking riluzole showed significant improvement on MADRS, CGI-S, and HAM-A scales. 126 Larger, controlled trials are needed to confirm these interesting preliminary findings.
Ionotropic glutamate receptors
Three different subgroups of glutamatergic ion channels have been identified utilizing their pharmacological ability to bind different synthetic ligands, each composed of a different set of subunits: N-methyl-DAspartate receptor (NMDA R), a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA R), and kainate receptor (KA R). The latter two groups are often referred to together as the 'non-NMDA' receptors ( Figure 2 ).
NMDA receptor
A growing body of preclinical and clinical research suggests that the NMDA receptor complex may be involved in the pathophysiology of mood disorders and the mechanism of action of antidepressants and possibly mood stabilizers (reviewed in Zarate et al 102 ) . NMDA receptor antagonists such as MK-801 and AP-7 and an AMPA receptor potentiator have been shown to have antidepressant properties in animal models of depression, including the forced swim test, the application of inescapable stressors, and tail suspension immobility tests, in animals exposed to chronic mild stress, and in the learned helplessness models of depression, effects that are comparable to the tricyclic antidepressants. [127] [128] [129] [130] [131] [132] MK-801 increases neurogenesis in the brains of rats. 133 There is evidence that the NMDA receptor antagonist, ketamine, has efficacy in the treatment of depression. Berman et al 134 reported the first placebo-controlled, double-blind trial assessing the treatment effects of a single dose of the NMDA receptor antagonist, ketamine, in seven patients with depression. The authors reported that subjects with depression experienced a significant improvement in depressive symptoms within a short period of time (72 h) after receiving ketamine but not after taking placebo. In addition, the ketamineinduced mood improvement persisted for 1-2 weeks after the infusion.
Additional evidence of the role of the glutamatergic system in mood disorders comes from associations of D-cycloserine and amantadine with affective symptoms (Figure 2 ). In the 1950s, D-cycloserine (DCS), a partial agonist at the NMDA receptor glycine site used as a part of multidrug antituberculosis treatment, was reported to have mood-elevating effects. [135] [136] [137] DCS has also been demonstrated to have antidepressant properties in animal models of depression. 138 Case series and blinded trials conducted with the noncompetitive NMDA antagonist amantadine additionally are supportive. At a high dose, amantadine reduces NMDA receptor function by approximately 50%, an effect attributed to its instability within the NMDA receptor channel. [139] [140] [141] Amantadine has been shown to have antidepressant effects in patients with Parkinson's disease and in unipolar and bipolar patients [142] [143] [144] but unlike its related compound, memantine, appears to have significant dopaminergic effects. Studies in progress are examining the possible therapeutic value of other NMDA receptor antagonists including memantine, Felbamate, and Zinc.
Memantine
Memantine has anticonvulsant and neuroprotective properties and has been shown in double-blind placebo-controlled studies to be effective in reducing clinical deterioration in Alzheimer's, vascular, and mixed dementia of all severities. [145] [146] [147] Chemically, memantine is a 1-amino-3,5-dimethyladamantane of the adamantine class, a compound that can easily cross the blood-brain barrier. Memantine is a potent noncompetitive voltage-dependent NMDA antagonist with a receptor effect comparable to MK-801 148 and has been demonstrated to inhibit [ 3 H]MK-801 binding to human hippocampal NMDA receptors. 149 Memantine appears to block the NMDA receptor-associated ion channel only when it is open for long periods, thus promoting the view that it may be specific for blockade of pathological glutamate release. Owing to this mechanism of action, the untoward effects of pathological concentrations of glutamate are prevented to a greater extent than the effects of physiological concentrations, which are relatively spared. 150, 151 Memantine has been safely used in humans in many clinical studies [145] [146] [147] and has been recently approved by the FDA for the treatment of Alzheimer's disorder. In preclinical studies, Moryl et al 152 described a dose-dependent decrease in the immobility time in the forced swim test in rats following administration of memantine. A synergistic effect was seen when imipramine and fluoxetine were given jointly with memantine in the forced swim test in rats. 153 Compared to the other NMDA antagonists, memantine has been reported to have the greatest effective potency for binding at the MK-801 receptor site in mouse brain as demonstrated by 18 fluorine-PET 154 and in human brain tissue. Memantine binds to the MK-801 binding site of the NMDA receptor in post-mortem human frontal cortex at therapeutic concentrations, 155 and reduces membrane currents.
148
Memantine is well tolerated and only a few isolated cases of psychosis (an effect of other NMDA antagonists such as ketamine) and cognitive deficits have been reported. In summary, memantine is one of the few NMDA antagonists available for use in humans and is ideal for testing in mood disorders, as it has been in clinical use for many years with minimal side effects and has a very favorable pharmacological profile.
Felbamate
Felbamate (2-phenyl-1, 3-propanediol dicarbamate) is a unique broad-spectrum anticonvulsant chemically related to the anxiolytic, meprobamate. 156 Felbamate exhibits neuroprotective properties in hypoxia-ischemia models, hippocampal traumatic injury models, and in excitotoxic insult in cell cultures. 157, 158 Ketter et al 159 reported stimulant-like effects with felbamate in patients with epilepsy and noted that half of the patients who received chronic open felbamate displayed modest psychiatric improvement compared to baseline. The authors summarized some of these positive reports with felbamate describing 'improved alertness, attention and concentration, as well as improved social, intellectual, mnestic and global function' and suggested that this drug may have antidepressant properties. 160 Gay et al 161 have reported improved attention, alertness, and initiative in children taking felbamate.
The therapeutic action of felbamate in refractory epilepsy may be related to novel noncompetitive antagonism (relative to NMDA and glycine) specifically at the NMDA NR1 and NR2B subunit. Felbamate appears to inhibit the function of the NMDA receptor complex through an interaction with the strychnineinsensitive glycine recognition site. Felbamate, but not carbamazepine or valproic acid, increased [ 3 H]5,7 DCKA glycine binding in rat brain and sections of human post-mortem brain. 162 Notably, the binding in human post-mortem brain increased by as much as 41% in CA2 region of the hippocampus 163 in comparison to carbamazepine and valproic acid. Thus, the anticonvulsant and neuroprotective effects of felbamate may act through the inhibition of NMDA receptor function via an allosteric modulation of the glycine site. 162, 164 In addition, felbamate has a four-to 10-fold preference for the NR2B-containing receptors 165 ( Figure 2 ) and at high concentrations, felbamate also enhances GABA A activity, inhibits AMPA/ kainite receptors, and inhibits dihydropyridine-sensitive calcium channels. 156 The use of felbamate has been limited by the unexpected increased risk of aplastic anemia and toxic hepatitis. 166 Despite these potentially life-threatening side effects, consideration should be given to the exploration of the use of felbamate in treatment-resistant mood disorders.
Zinc
Zinc is a potent inhibitor of the NMDA receptor, plays an important role in a wide range of biochemical processes, 167 and could have a role in the treatment of mood disorders. Chronic electroconvulsive shock treatment of rats was reported to be associated with an increase in the zinc concentration in the hippocampus. 168 Recently, zinc has been reported to have antidepressant-like properties in forced swim test and olfactory bulbectomy model in rats. [169] [170] [171] In humans, although an indirect indication of CNS zinc levels, lower zinc blood concentrations were found in depressed patients, which normalized after successful antidepressant therapy. 168, 172, 173 In a placebocontrolled study, adjunctive treatment with zinc has recently been shown to have antidepressant effects. 174 Interestingly, zinc, like lithium, inhibits the enzyme glycogen synthase kinase-3 (GSK-3). 175 Thus, future studies will need to differentiate between the NMDA and GSK-3 effects of zinc.
AMPA receptor AMPA receptors are a subfamily of ionotropic glutamate receptors that mediate the fast component of excitatory neurotransmission, which, like NMDA receptors, are involved in learning and memory. Several classes of compounds can allosterically modulate AMPA receptors. These compounds (the so-called AMPA receptor positive modulators or AMPA receptor potentiators, ARPs) do not activate AMPA receptors themselves but slow the rate of receptor desensitization and/or deactivation in the presence of an agonist (eg glutamate and AMPA) (see Borges and Dingledinc, 176 Bleakman and Lodge 177 for a review). AMPAkines, a subclass of ARPs, are small benzamide compounds that allosterically produce positive modulation of AMPA receptors that have actively been studied in the treatment of schizophrenia. 178 Studies have shown that the biarylpropylsulfonamide AMPA receptor potentiators (LY392098 and LY451616) have antidepressant effects in animal models of depression (including the application of inescapable stressors, forced swim test, and tailsuspension-induced immobility tests), in learned helplessness models of depression, and in animals exposed to chronic mild stress procedure. 127 In one of these preclinical studies, the AMPAkine, Ampalex was reported to have a more rapid effect (during the first week of treatment) than fluoxetine (after 2 weeks). 179 In contrast to traditional antidepressants, this group of compounds does not appear to affect the extracellular concentration of monoamines. 180 However, they can enhance the neurotrophic actions of brain-derived neurotrophic factor (BDNF) mRNA and protein in primary neuronal cultures. 181 Modulation of neurotrophic factor expression and altering the rate of neurogenesis may be critical factors in understanding the therapeutic effects of antidepressants and mood stabilizers in mood disorders. In support, chronic treatment with the AMPA receptor potentiator LY451646 increased progenitor cell proliferation in the dentate gyrus in a dose-dependent manner. The antidepressant-like activity of ARPs in animals may be attributed, at least in part, to the regulation of cell proliferation in the hippocampus. 182 ( Figure 2 ).
Metabotropic glutamate receptors
In addition to the ionotropic receptors, three groups compromised of eight G-protein-coupled metabotropic glutamate receptors (mGluR) mediate slower modulatory actions of glutamate on neurotransmitter release and cell excitability ( Figure 2 ). Activation of mGluR leads to a variety of cellular responses, including the inhibition of calcium and potassium currents, presynaptic modulation of synaptic transmission, and postsynaptic interaction with ionotropic glutamate receptors. [183] [184] [185] The mGluR are involved in the early phase of memory formation and the mechanism of long-term depression. [186] [187] [188] Group I mGluRs have been found to exhibit potential therapeutic effects in CNS disorders related to excess excitatory neurotransmission such as epilepsy, pain, and ischemia (see Nicoletti et al 189 for a review). Preclinical studies suggest that mGlu 2/3 agonists have antianxiety, antipsychotic, and neuroprotective properties. 190, 191 However, selective activation/antagonism of various mGluRs can lead to either anxiolytic-and/or antidepressant-like effects [192] [193] [194] [195] and specific interactions of each receptor subtype are an intensive area of investigation (see Zarate et al 102 for a review). Taking into account that every group of mGluR (see Figure 2) can simultaneously couple with different subgroups of G-protein subunits, and that interactions with glutamate ionotropic receptors and other ion channels have been described, this complex system offers a tremendous potential in the search for novel therapeutic strategies in CNS disorders (including mood disorders).
In conclusion, there is ample evidence from preclinical and clinical research that the glutamatergic system is involved in the pathophysiology of mood disorders and that testing of glutamate-modulating agents in 'proof-of-concept' studies may provide an insight into the pathophysiology of mood disorders and may help open a new pathway for drug development. It should be acknowledged that many of the drugs reviewed here have effects on the other neurotransmitter systems in addition to their often, indirect effects on glutamate function.
Strategies to potentiate neurotrophic cascades for the treatment of bipolar disorder
There is a growing body of data suggesting that agents that directly modulate neurotrophic cascades, such as the CREB/BDNF/bcl-2 cascade, may have utility for the treatment of mood disorders (see Figure 3 and D'sa and Duman 20 for a review). Specifically, they may represent a mechanism to attenuate or reverse the deficits in neuroplasticity and cellular resilience observed in patients with bipolar disorder described earlier in this article. One approach to increase CREB activity, and thus neurotrophic signaling (Figure 3 ), utilizes inhibition of phosphodiesterase (PDE), the enzymes responsible for the breakdown of cAMP. Adenylate cyclase-mediated production of cAMP One major downstream target of PKA is CREB (cAMP response element binding protein). After activation, phosphorylated CREB binds to the cAMP response element (CRE), a gene sequence found in the promoter of certain genes (including BDNF and bcl-2); recent data suggest that antidepressants 196 and also mood-stabilizing drugs 231 may activate CREB, thereby bringing about increased expression of a major target gene, BDNF. Phosphodiesterase is an enzyme that breaks down cAMP to AMP. Drugs like rolipram, which inhibit phosphodiesterase, may be useful as adjunct treatments for depression. Thus, it is hypothesized that phosphodiesterase inhibitors may represent a distinct class of treatments for mood disorders, perhaps acting by increasing the activity of neurotrophic signaling pathways and attenuating impairments in neuroplasticity and cellular resilience associated with these illnesses.
leads to the activation of protein kinase A and subsequent phosphorylation-mediated activation of CREB. CREB, in turn, increases transcription of many genes including BDNF and bcl-2 (see Duman 196 for a review). In this context, Takahashi et al. 197 demonstrated that chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase (PDE) 4A and 4B isoforms; these effects likely represent a compensatory 'counter-regulatory' response to the chronic antidepressant administration. 198 These data suggest that PDE4A and PDE4B may be relevant targets for the development of agents that possess antidepressant effects either as monotherapy, or in combination with agents that increase intrasynaptic monoamine levels, due to the possible synergism of effects on the cAMP cascade. Preclinical studies conducted to date do support the potential utility of PDE4 inhibitors in the treatment of depressive disorders. Thus, long-term administration of PDE4 inhibitors increases the expression of CREB and BDNF in the hippocampus of rats, 199, 200 and PDE inhibitors likewise have antidepressant-like effects in behavioral models. [201] [202] [203] Indeed, the idea that PDE inhibitors may have potential antidepressant activity is not a new one, and was initially proposed by Wachtel in the early 1980s. 203 In the 1980s and early 1990s, a number of open 204 and controlled clinical trials [205] [206] [207] [208] demonstrated that rolipram, a specific inhibitor of the highaffinity cAMP PDE4, may have antidepressant efficacy in depressed patients. In addition, there is evidence that rolipram may have a faster onset of response compared to the standard antidepressants. In a clinical study by Horowski et al, 209 a rapid antidepressant effect to rolipram was reported to occur within the first 12 h to 10 days, and another study 204 reported an antidepressant effect only after 2 to 4 days of treatment. However, a randomized double-blind comparative trial of rolipram vs imipramine carried out by Hebenstreit et al 207 found that imipramine was more effective than rolipram, although both were beneficial. Further, in a controlled study by Scott et al, 210 they concluded that amitriptyline was more effective than rolipram in the treatment of depressed inpatients. Although the overall literature on the use of rolipram is suggestive that PDE inhibitors may have antidepressant efficacy and may have a faster onset of action, the potential use of rolipram for depression was limited because of side effects such as nausea and emesis.
Recent studies demonstrating that PDE4 is expressed in inflammatory cells such as eosinophils and that inhibition of PDE4 downregulates the inflammatory response, has generated renewed excitement about the possible utility of this class of agents in the treatment of diseases such as asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, Crohn's disease, and multiple sclerosis (MS). 211, 212 Second-generation compounds with markedly improved tolerability are rapidly being developed, 211, 212 and it is anticipated that the availability of CNS-penetrant PDE4 inhibitors may lead to the development of a novel class of antidepressants. Importantly, some mood stabilizers may attenuate adenylate cyclase mediated signaling-and that this represents a putative mechanism of action (see Gould et al 2 for a review). Thus, future preclinical studies will likely discern region and cell specificity of these findings.
Human phase I/II trials of recombinant methionyl human brain-derived neurotrophic factor have already been undertaken, wherein the BDNF was administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. 213 Unfortunately, side effects such as sensory symptoms, including paresthesias or a sense of warmth, sleep disturbance, dry mouth, agitation, and other behavioral effects were encountered at higher doses, precluding further study.
An increasing number of strategies are being investigated to develop small molecule switches for protein-protein interactions, which have the potential to regulate the activity of growth factors, MAP kinases cascades, and interactions between homoand heterodimers of the bcl-2 family of proteins. In view of the robust effects of bcl-2 on neurite sprouting, neurite outgrowth and axonal regeneration, [214] [215] [216] [217] [218] and protection against the deleterious CNS effects of severe stress, 219 it is quite possible that bcl-2 enhancers will have utility in the treatment of bipolar disorder. Indeed, lithium's ability to upregulate bcl-2 robustly may play a role in many of its therapeutic effects. It is also worth noting that pramipexole also upregulates bcl-2 in several brain areas, 220 and has been shown to exert antidepressant effects. 221 While the dopamine agonistic effects of pramipexole may clearly also contribute to its purported antidepressant effects, its robust neurotrophic effects suggest that it may have broader utility as an antidepressant potentiator. In this context, recent studies at the NIMH 221 and elsewhere 222 have found pramipexole to be more effective than placebo in treating bipolar depression; ongoing longitudinal studies at the NIMH are further exploring putative neurotrophic effects with the use of serial MRS measurements of NAA, and volumetric MRIs.
Conclusions
Bipolar disorder is a devastating disorder, which exerts a major toll on millions of sufferers worldwide. While recent years have seen the introduction of a large number of agents into the pharmacopeia and undoubtedly provides the clinician with many more choices, there has been little progress in developing truly novel drugs specifically for the illness. Currently available medications have-by and large-been developed for the treatment of other disorders like epilepsy or schizophrenia, and therefore are not optimal in the treatment of bipolar disorder, prevention of relapses, improving functioning, or treating the deleterious effects of this illness on other organ systems. We propose that new medications will likely derive from both understanding mechanisms of current drug actions and by directing medications at critical 'signaling nodes' determined to be at the nexus of interacting intracellular cascades.
Evolving theories of bipolar disorder neurobiology are attempted to elucidate the complex interaction of multiple susceptibility (and protective) genes and environmental factors that regulate cellular plasticity. These interactions result in the phenotypic expression of a disease that includes not only episodic and often profound mood disturbance but also a constellation of cognitive, motoric, autonomic, endocrine, sleep/wake abnormalities, 223 and possibly other systemic manifestations. Numerous genetic loci have been associated with bipolar disorder and it is likely that specific gene mutations associated with the illness will soon be identified. This endeavor will undoubtedly uncover reproducible susceptibility genes; however, the next task will involve placing the complex picture together-using molecular, cellular, circuit, and behavioral neuroscience-with pathophysiological theories of the origins of bipolar disorder. Modulation of the HPA axis through inhibition of CRH receptors, glucocorticoid receptors, or other means such as glucocorticoid synthesis may designate a novel class of medications that directly target pathophysiological processes involved in mood disorders. As we discussed, there is a growing body of data suggesting that agents that modulate the glutamatergic system may have utility in the long-term treatment of severe mood disorders. In general, glutamatergic 'plasticity-enhancing' strategies include inhibitors of glutamate release agents, NMDA antagonists, AMPA potentiators, and metabotropic receptor agonists/antagonists. Thus, neuroprotective strategies used for the treatment of neurodegenerative disorders may have an important role in the treatment of mood disorders, and are currently being tested in 'proof-ofconcept' studies in patients. Phosphodiesterase inhibitors may additionally be advantageous as a mechanism to increase the levels of neurotrophic molecules such as BDNF and bcl-2, which are responsive to increases in CREB. Such studies may ultimately lead to a better understanding of the pathophysiology of recurrent unipolar depression and bipolar disorder, and result in the development of improved therapeutics. It is critical to remember that while theories abound, ultimate validation (especially considering available animal models of bipolar disorder 224, 225 ) will rest in the results of clinical trials. This is not likely to be a simple process, and indeed numerous methodological and study design issues have emerged from both controlled randomized trials and various longitudinal observations of bipolar disorder patients followed for up to 20 years. Some of these methodological concerns, which have been eloquently articulated elsewhere, 225, 227 include the following: (i) there are multiple subtypes of clinical presentation embedded in current diagnosis; (ii) multiple response possibilities are present; (iii) there appear to be changing response patterns over time; (iv) inadequate attention is paid to combination treatments; and (v) there are high drop out and noncompliance rates. When considering the complexity, morbidity, and mortality of bipolar disorder, it has been suggested that the desired attribute of ideal new agents for the treatment of bipolar disorder should include as many of the following attributes as possible: 226, 227 (i) efficacy in the treatment of acute hypomania/mania; (ii) efficacy in the treatment of acute depression; (iii) efficacy in the acute treatment of mixed states; (iv) efficacy in the treatment of acute episodes associated with rapid cycling bipolar disorder; (v) reducing subsyndromes or residual mood symptoms; (vi) efficacy in the treatment of psychotic symptoms that frequently accompany depressive or manic episodes; (v) ability to prevent both relapses and recurrences; (vi) reducing the need for concomitant medications; (vii) preventing suicide; (viii) decreasing time-ill; (ix) decreasing substance abuse and other comorbidities; (x) preventing/reducing chronicity; (xi) improving cognition and preventing cognitive decline; (xii) restoring full social and occupational functioning and quality of life; (xiii) rapidly acting; (xiv) few side effects; and (xv) preventing the systematic manifestations resulting from mood episodes.
It is clear that we will never develop such ideal magic bullets; however, as we have outlined here, evidence derived from neuroimaging, post-mortem brain, biochemical and pharmacologic studies all support the contention that impairments of cellular plasticity and resilience are integral to the pathophysiology of bipolar disorder. Furthermore, a growing body of data suggest that although bipolar disorder is not a classical mitochondrial disorder, many of the upstream abnormalities (likely nuclear genome coded) converge to regulate mitochondrial function implicated both in abnormalities of neurotransmitter synaptic plasticity and long-term cellular resilience. [240] [241] [242] [243] There is growing apprecition that neuronal mitochondria participate not only in oxidative phosphorylation and -in networks with ER-in calcium uptake, but also in cellular resilience and neurotransmitter synaptic function. Thus, agents capable of reversing the mitochondrial-driven impairments of cellular plasticity and resilience in biplolar disorder have the potential of becoming new therapeutic classes of mood-stabilizing drugs. Agents capable actively being investigated include pramipexole (a bcl-2 enhancer), coenzyme Q10 and carnitine (respirtory chain enhancers). 246 It is our contention that targeting these cellular plasticity cascades will lead to truly novel (and hopefully improved) treatements for these devastating illnesses.
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